Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin's gastric lymphoma patients

World Journal of Gastroenterology

Volumn 12, Issue 12, 2006, Pages 1924-1932

  Darom, Alexander ^a   Gomatos, Ilias P ^a,b   Leandros, Emmanuel ^a   Chatzigianni, Emmu ^a   Panousopoulos, Dimitris ^a   Konstadoulakis, Manousos M ^a   Androulakis, Goeorge ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

HLA DR; ICAM 3; Non Hodgkin's gastric lymphoma; PECAM 1; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CD31 ANTIGEN; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 3; MOLECULAR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; FEMALE; GASTRECTOMY; GENE EXPRESSION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; INFLAMMATORY INFILTRATE; MAJOR CLINICAL STUDY; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PROGNOSIS; STOMACH LYMPHOMA; STOMACH MUCOSA; SURVIVAL RATE; TOTAL STOMACH RESECTION; TUMOR GROWTH; UNIVARIATE ANALYSIS;

EID: 33645980937     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i12.1924     Document Type: Article

References (58)

1. Frazee RC, Roberts J. Gastric lymphoma treatment. Medical versus surgical. Surg Clin North Am 1992; 72: 423-431
2. Azab MB, Henry-Amar M, Rougier P, Bognel C, Theodore C, Carde P, Lasser P, Cosset JM, Caillou B, Droz JP. Prognostic factors in primary gastrointestinal non-Hodgkin's lymphoma. A multivariate analysis, report of 106 cases, and review of the literature. Cancer 1989; 64: 1208-1217
3. Pozzi B, Hotz AM, Feltri M, Cornaggia M, Campiotti L, Bonato M, Pinotti G, Capella C. Primary gastric lymphomas. Clinico-pathological study and evaluation of prognostic factors in 65 cases treated surgically Pathologica 2000; 92: 503-515
4. Charalambous GK, Gomatos IP, Konstadoulakis MM, Messaris EG, Manouras AJ, Apostolou AE, Leandros EA, Karayannis MK, Androulakis GA. Protein expression of bax, bcl-2, and p53 in patients with non-Hodgkin's gastric lymphoma: prognostic significance. World J Surg 2000; 24: 608-614
5. Benacerraf B. Role of MHC gene products in immune regulation. Science 1981; 212: 1229-1238
6. Kaufman JF, Auffray C, Korman AJ, Shackelford DA, Strominger J. The class II molecules of the human and murine major histocompatibility complex. Cell 1984; 36: 1-13
7. Muller C, Ziegler A, Muller C, Hadam M, Waller HD, Wernet P, Muller G. Divergent expression of HLA-DCIMB, -DR, and -SB region products on normal and pathological tissues as detected by monoclonal antibodies. Immunobiology 1985; 169: 228-249
8. Ghosh AK, Moore M, Street AJ, Howat JM, Schofield PF. Expression of HLA-D sub-region products on human colorectal carcinoma. Int J Cancer 1986; 38: 459-464
9. Festenstein H. The biological consequences of altered MHC expression on tumours. Br Med Bull 1987; 43: 217-227
10. Holness CL, Bates PA, Little AJ, Buckley CD, McDowall A, Bossy D, Hogg N, Simmons DL. Analysis of the binding site on intercellular adhesion molecule 3 for the leukocyte integrin lymphocyte function-associated antigen 1. J Biol Chem 1995; 270: 877-884
11. Fawcett J, Holness CL, Needham LA, Turley H, Gatter KC, Mason DY, Simmons DL. Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature 1992; 360: 481-484
12. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120-1124
13. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6
14. Umansky V, Schirrmacher V, Rocha M. New insights into tumor-host interactions in lymphoma metastasis. J Mol Med 1996; 74: 353-363
15. Fidler IJ. Host and tumour factors in cancer metastasis. Eur J Clin Invest 1990; 20: 481-486
16. Goulding H, Abdul Rashid NF, Robertson JF, Bell JA, Elston CW, Blarney RW, Ellis IO. Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? Hum Pathol 1995; 26: 1196-1200
17. Weider N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409
18. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993; 178: 449-460
19. Jarry A, Brousse N, Souque A, Barge J, Molas G, Potet F. Lymphoid stromal reaction in gastrointestinal lymphomas: immunohistochemical study of 14 cases. J Clin Pathol 1987; 40: 760-765
20. Jaskiewicz K, Kobierska G. Lymphoid aggregates in gastric biopsies: relationship to other mucosal lesions. Arch Immunol Ther Exp (Warsz) 2000; 48: 201-204
21. Sato Y, Ito M, Morise K, Saito Y, Kusugami K. Expression of adhesion molecules in primary B-cell gastric lymphoma and lymphoid follicles. Virchows Arch 1996; 429: 377-382
22. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma 13th ed. Tokyo: Kanehara Pub, 1999: 1-105
23. Aoyagi K, Kohfuji K, Yano S, Murakami N, Miyagi M, Takeda J, Shirouzu K. The expression of proliferating cell nuclear antigen, p53, p21, and apoptosis in primary gastric lymphoma. Surgery 2002; 132: 20-26
24. Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 1995; 221: 706-18; discussion 718-720
25. Cox G, Walker RA, Andi A, Steward WP, O'Byrne KJ, Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer 2000; 29: 169-177
26. Penfold CN, Partridge M, Rojas R, Langdon JD. The role of angiogenesis in the spread of oral squamous cell carcinoma. Br J Oral Maxillofac Surg 1996; 34: 37-41
27. Aozasa K, Tsujimoto M, Inoue A, Nakagawa K, Hanai J, Kurata A, Nosaka J. Primary gastrointestinal lymphoma. A clinicopathologic study of 102 patients. Oncology 1985; 42: 97-103
28. Rosen CB, van Heerden JA, Martin JK Jr, Wold LE, Ilstrup DM. Is an aggressive surgical approach to the patient with gastric lymphoma warranted? Ann Surg 1987; 205: 634-640
29. Bozer M, Eroglu A, Unal E, Eryavuz Y, Kocaoglu H, Demirci S. Survival after curative resection for stage IE and IIE primary gastric lymphoma. Hepatogastroenterology 2001; 48: 1202-1205
30. Tsang RW, Gospodarowics MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, Crump M. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 50: 1258-1264
31. Ferreri AJ, Ponzoni M, Pruneri G, Freschi M, Rossi R, Dell'Oro S, Baldini L, Buffa R, Carboni N, Villa E, Viale G. Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. Int J Cancer 2001; 94: 599-604
32. Takeshita M, Iwashita A, Kurihara K, Ikejiri K, Higashi H, Udoh T, Kikuchi M. Histologic and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma. Am J Surg Pathol 2000; 24: 1641-1649
33. Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F. Tumor aggressiveness and A4HC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 1991; 2: 47-54
34. Sikorska B, Danilewicz M, Wagrowska-Danilewicz M. HLA-DR expression is a significant prognostic factor in laryngeal cancer. A morphometric study. APMIS 1999; 107: 383-388
35. Bodmer WF. The HLA system: structure and function. J Clin Pathol 1987; 40: 948-958
36. Hilton DA, West KP. An evaluation of the prognostic significance of HLA-DR expression in gastric carcinoma. Cancer 1990; 66: 1154-1157
37. Hawley PR, Westerholm P, Morson BC. Pathology and prognosis of carcinoma of the stomach. Br J Surg 1970; 57: 877-883
38. Elangbam CS, Qualls CW Jr, Dahlgren RR. Cell adhesion molecules-update. Vet Pathol 1997; 34: 61-73
39. Charpin C, Garcia S, Bouvier C, Martini F, Andrac L, Bonnier P, Lavaut MN, Allasia C. CD3VPECAM automated and quantitative immunocytochemical assays in breast carcinomas: correlation with patient follow-up. Am J Clin Pathol 1997; 107: 534-541
40. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875-1887
41. Zhou J, Sargiannidou I, Tuszynski GP. The role of adhesive proteins in the hematogenous spread of cancer. In Vivo 2000; 14: 199-208
42. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999; 18: 345-357
43. Drillenburg P, Pals ST. Cell adhesion receptors in lymphom dissemination. Blood 2000; 95: 1900-1910
44. Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 1993; 55: 371-374
45. Vlaykova T, Muhonen T, Hahka-Kemppinen M, Pyrhonen S, Jekunen A. Vascularity and prognosis of metastatic melanoma. Int J Cancer 1997; 74: 326-329
46. Giatromanolaki A, Sivridis E, Minopoulos G, Polychronidis A, Manolas C, Simopoulos C, Koukourakis MI. Differential assessment of vascular survival ability and tumor angiogenic activity in colorectal cancer. Clin Cancer Res 2002; 8: 1185-1191
47. Anastassiou G, Duensing S, Steinhoff G, Zorn U, Grosse J, Dallmann I, Kirchner H, Ganser A, Atzpodien J. Platelet endothelial cell adhesion molecule-1 (PECAM-1): a potential prognostic marker involved in leukocyte infiltration of renal cell carcinoma. Oncology 1996; 53: 127-132
48. Sawa Y, Yamaoka Y, Ebata N, Ashikaga Y, Kim T, Suzuki M, Yoshida S. Immunohistochemical study on leukocyte adhesion molecules expressed on lymphatic endothelium: Microvasc Res 1999; 57: 292-297
49. Sawa Y, Yoshida S, Ashikaga Y, Kim T, Yamaoka Y, Shiroto H. Lymphatic endothelium expresses PECAM-1. Tissue Cell 1998; 30: 377-382
50. Nagy JA, Brown LF, Senger DR, Lanir N, Van de Water L, Dvorak AM, Dvorak HF. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989; 948: 305-326
51. Gross JL, Moscatelli D, Jaffe EA, Rifkin DB. Plasminogen activator and collagenase production by cultured capillary endothelial cells. J Cell Biol 1982; 95: 974-981
52. Ogawa Y, Hirakawa K, Nakata B, Fujihara T, Sawada T, Kato Y, Yoshikawa K, Sowa M. Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res 1998; 4: 31-36
53. Pircher H, Groscurth P, Baumhutter S, Aguet M, Zinkernagel RM, Hengartner H. A monoclonal antibody against altered LFA-1 induces proliferation and lymphokine release of cloned T cells. Eur J Immunol 1986; 16: 172-181
54. Patarroyo M, Makgoba MW. Leucocyte adhesion to cells. Molecular basis, physiological relevance, and abnormalities. Scand J Immunol 1989; 30: 129-164
55. Hernandez-Caselles T, Rubio G, Campanero MR, del Pozo MA, Muro M, Sanchez-Madrid F, Aparicio P. ICAM-3, the third LFA-1 counterreceptor, is a co-stimulatory molecule for both resting and activated T lymphocytes. Eur J Immunol 1993; 23: 2799-2806
56. Terol MJ, Cid MC, Lopez-Guillermo A, Juan M, Yague J, Miralles A, Vilella R, Vives J, Cardesa A, Montserrat E, Campo E. Expression of intercellular adhesion molecule-3 (ICAM-3/CD50) in malignant lymphoproliferative disorders and solid tumors. Tissue Antigens 1996; 48: 271-277
57. Molica S, Dattilo A, Mannella. A, Levato D. Intercellular adhesion molecules (ICAMs) 2 and 3 are frequently expressed in B cell chronic lymphocytic leukemia. Leukemia 1996; 10: 907-908
58. Hosch SB, Izbicki JR, Pichhneier U, Stoecklein N, Niendorf A, Knoefel WT, Broelsch CE, Pantel K. Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer 1997; 74: 582-587